333 related articles for article (PubMed ID: 36217774)
1. Low-molecular weight inhibitors of the alternative complement pathway.
Schubart A; Flohr S; Junt T; Eder J
Immunol Rev; 2023 Jan; 313(1):339-357. PubMed ID: 36217774
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
3. Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.
Dobó J; Kocsis A; Gál P
Front Immunol; 2018; 9():1851. PubMed ID: 30135690
[TBL] [Abstract][Full Text] [Related]
4. Diseases of complement dysregulation-an overview.
Wong EKS; Kavanagh D
Semin Immunopathol; 2018 Jan; 40(1):49-64. PubMed ID: 29327071
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
Lorthiois E; Anderson K; Vulpetti A; Rogel O; Cumin F; Ostermann N; Steinbacher S; Mac Sweeney A; Delgado O; Liao SM; Randl S; Rüdisser S; Dussauge S; Fettis K; Kieffer L; de Erkenez A; Yang L; Hartwieg C; Argikar UA; La Bonte LR; Newton R; Kansara V; Flohr S; Hommel U; Jaffee B; Maibaum J
J Med Chem; 2017 Jul; 60(13):5717-5735. PubMed ID: 28621538
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.
Karki RG; Powers J; Mainolfi N; Anderson K; Belanger DB; Liu D; Ji N; Jendza K; Gelin CF; Mac Sweeney A; Solovay C; Delgado O; Crowley M; Liao SM; Argikar UA; Flohr S; La Bonte LR; Lorthiois EL; Vulpetti A; Brown A; Long D; Prentiss M; Gradoux N; de Erkenez A; Cumin F; Adams C; Jaffee B; Mogi M
J Med Chem; 2019 May; 62(9):4656-4668. PubMed ID: 30995036
[TBL] [Abstract][Full Text] [Related]
7. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
Front Immunol; 2020; 11():1460. PubMed ID: 32793201
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule factor D inhibitors targeting the alternative complement pathway.
Maibaum J; Liao SM; Vulpetti A; Ostermann N; Randl S; Rüdisser S; Lorthiois E; Erbel P; Kinzel B; Kolb FA; Barbieri S; Wagner J; Durand C; Fettis K; Dussauge S; Hughes N; Delgado O; Hommel U; Gould T; Mac Sweeney A; Gerhartz B; Cumin F; Flohr S; Schubart A; Jaffee B; Harrison R; Risitano AM; Eder J; Anderson K
Nat Chem Biol; 2016 Dec; 12(12):1105-1110. PubMed ID: 27775713
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Schubart A; Anderson K; Mainolfi N; Sellner H; Ehara T; Adams CM; Mac Sweeney A; Liao SM; Crowley M; Littlewood-Evans A; Sarret S; Wieczorek G; Perrot L; Dubost V; Flandre T; Zhang Y; Smith RJH; Risitano AM; Karki RG; Zhang C; Valeur E; Sirockin F; Gerhartz B; Erbel P; Hughes N; Smith TM; Cumin F; Argikar UA; Haraldsson B; Mogi M; Sedrani R; Wiesmann C; Jaffee B; Maibaum J; Flohr S; Harrison R; Eder J
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7926-7931. PubMed ID: 30926668
[TBL] [Abstract][Full Text] [Related]
10. Complement Dysregulation and Disease: Insights from Contemporary Genetics.
Liszewski MK; Java A; Schramm EC; Atkinson JP
Annu Rev Pathol; 2017 Jan; 12():25-52. PubMed ID: 27959629
[TBL] [Abstract][Full Text] [Related]
11. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration.
Richards A; Kavanagh D; Atkinson JP
Adv Immunol; 2007; 96():141-77. PubMed ID: 17981206
[TBL] [Abstract][Full Text] [Related]
12. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome.
Berger BE
Am J Med Sci; 2016 Aug; 352(2):177-90. PubMed ID: 27524217
[TBL] [Abstract][Full Text] [Related]
13. Scaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors.
Zhang W; Wu M; Vadlakonda S; Juarez L; Cheng X; Muppa S; Chintareddy V; Vogeti L; Kellogg-Yelder D; Williams J; Polach K; Chen X; Raman K; Babu YS; Kotian P
Bioorg Med Chem; 2022 Nov; 74():117034. PubMed ID: 36272185
[TBL] [Abstract][Full Text] [Related]
14. [Atypical hemolytic uremic syndrome caused by primary complement defects].
Reusz G
Orv Hetil; 2018 Jun; 159(23):929-936. PubMed ID: 29860884
[TBL] [Abstract][Full Text] [Related]
15. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
Michels MAHM; van de Kar NCAJ; Volokhina EB; van den Heuvel BLPWJ
Methods Mol Biol; 2021; 2227():83-96. PubMed ID: 33847933
[TBL] [Abstract][Full Text] [Related]
16. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation.
Frazer-Abel A; Sepiashvili L; Mbughuni MM; Willrich MA
Adv Clin Chem; 2016; 77():1-75. PubMed ID: 27717414
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
Risitano AM; Marotta S
Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
[TBL] [Abstract][Full Text] [Related]
18. A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway.
Vaught AJ; Braunstein E; Chaturvedi S; Blakemore K; Brodsky RA
J Matern Fetal Neonatal Med; 2022 Apr; 35(7):1392-1400. PubMed ID: 32338085
[TBL] [Abstract][Full Text] [Related]
19. Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome.
Zhang Y; Kremsdorf RA; Sperati CJ; Henriksen KJ; Mori M; Goodfellow RX; Pitcher GR; Benson CL; Borsa NG; Taylor RP; Nester CM; Smith RJH
Kidney Int; 2020 Nov; 98(5):1265-1274. PubMed ID: 32540405
[TBL] [Abstract][Full Text] [Related]
20. The spectrum of complement alternative pathway-mediated diseases.
Holers VM
Immunol Rev; 2008 Jun; 223():300-16. PubMed ID: 18613844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
